{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:00:24Z","timestamp":1781067624450,"version":"3.54.1"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The treatment of Multiple myeloma (MM) has been revolutionized by the advent of immunotherapies. Monoclonal antibodies targeting specific markers greatly contributed to patients\u2019 outcome improvement. Antibodies can be conjugated with a toxic payload to exert anti-tumor efficacy (antibody\u2013drug conjugates, ADCs). ADCs combine direct cytotoxicity with immune-mediated effects, potentially sustaining antimyeloma activity even with prolonged dosing intervals. B-cell maturation antigen (BCMA) is selectively expressed on plasma cells, including malignant clones and represents a validated target in MM. Belantamab-mafodotin is the first in class anti-BCMA ADC approved in MM. The drug demonstrated single agent activity in heavily pretreated MM patients enrolled in the phase II DREAMM-2 trial. However, the confirmatory phase III DREAMM-3 trial failed to show superiority over standard therapy, leading to a temporary withdrawal of its approval by regulatory agencies. Despite this setback, recent data from the DREAMM-7 and DREAMM-8 trials have renewed interest in Belantamab-mafodotin, showing a benefit over standard of care treatments when evaluated in earlier lines of therapy and in combination with known therapeutic backbones. Recently, other ADCs against BCMA or other targets are being developed. This review aims to explore the current clinical positioning of ADCs within MM therapeutic landscape and their possible future development.<\/jats:p>","DOI":"10.3389\/fonc.2026.1822419","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:31:07Z","timestamp":1781065867000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Current positioning and future development of belantamab mafodotin and other antibody-drug conjugates to treat multiple myeloma"],"prefix":"10.3389","volume":"16","author":[{"given":"Giuseppe","family":"Bertuglia","sequence":"first","affiliation":[{"name":"Division of Hematology, Azienda Ospedaliera Universitaria (AOU) Citt\u00e0 della Salute e della Scienza di Torino, Department of Molecular Biotechnology and Health Sciences, University of Torino","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Di Nicola","sequence":"additional","affiliation":[{"name":"Division of Hematology, Azienda Ospedaliera Universitaria (AOU) Citt\u00e0 della Salute e della Scienza di Torino, Department of Molecular Biotechnology and Health Sciences, University of Torino","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[{"name":"Division of Hematology, Azienda Ospedaliera Universitaria (AOU) Citt\u00e0 della Salute e della Scienza di Torino, Department of Molecular Biotechnology and Health Sciences, University of Torino","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Larocca","sequence":"additional","affiliation":[{"name":"Division of Hematology, Azienda Ospedaliera Universitaria (AOU) Citt\u00e0 della Salute e della Scienza di Torino, Department of Molecular Biotechnology and Health Sciences, University of Torino","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[{"name":"Division of Hematology, Azienda Ospedaliera Universitaria (AOU) Citt\u00e0 della Salute e della Scienza di Torino, Department of Molecular Biotechnology and Health Sciences, University of Torino","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"D\u2019Agostino","sequence":"additional","affiliation":[{"name":"Division of Hematology, Azienda Ospedaliera Universitaria (AOU) Citt\u00e0 della Salute e della Scienza di Torino, Department of Molecular Biotechnology and Health Sciences, University of Torino","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody\u2013drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-017-0397-7","article-title":"Novel immunotherapies for multiple myeloma","volume":"12","author":"D\u2019Agostino","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.014","article-title":"Immuno-oncologic approaches: CAR-T cells and checkpoint inhibitors","volume":"17","author":"Gay","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph16040590","article-title":"Antibody\u2013drug conjugates for multiple myeloma: just the beginning, or the beginning of the end","volume":"16","author":"Ray","year":"2023","journal-title":"Pharmaceuticals"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0618","article-title":"FDA approval summary: Belantamab mafodotin for patients with relapsed or refractory multiple myeloma","volume":"28","author":"Baines","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13592","article-title":"EMA review of belantamab mafodotin (Blenrep) for the treatment of adult patients with relapsed\/refractory multiple myeloma","volume":"26","author":"Tzogani","year":"2021","journal-title":"Oncologist"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00243-0","article-title":"Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/nejmoa2405090","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2403407","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/0010-938x(95)90006-t","article-title":"Stock-exchange announcement For media and investors only Blenrep approved by US FDA for use in treatment of relapsed \/ refractory multiple myeloma Stock-exchange announcement For media and investors only","author":"Wood","year":"2025"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA\u2013EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s2152-2650(25)03879-0","article-title":"Optimizing belantamab mafodotin doses for the treatment of transplant-ineligible newly diagnosed multiple myeloma in the DREAMM-9 study background and aims background","volume":"25","author":"Uzmani","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025031629","article-title":"Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma","volume":"147","author":"Terpos","year":"2026","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6679101","DOI":"10.1038\/s41375-024-02505-2","article-title":"Design of the phase 3 DREAMM-10 study: Belantamab mafodotin plus lenalidomide and dexamethasone (BRd) vs daratumumab plus lenalidomide and dexamethasone (DRd) in transplant-ineligible, newly diagnosed multiple myeloma (TI-NDMM)","volume":"144","author":"Lonial","year":"2024"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)03452-4","article-title":"OA-48 - Final analysis of the GEM-BELA-VRd phase II trial: Belantamab mafodotin plus VRd in newly diagnosed transplant-eligible myeloma after 2 years of maintenance with belantamab and lenalidomide","author":"Martinez-Lop","year":"","journal-title":"Oral Present Vol 25 Suppl 2S32-S33 Sept 2025"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02505-2","article-title":"Daratumumab \/ lenalidomide \/ dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes","volume":"39","author":"Facon","year":"2025","journal-title":"Leukemia"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025746","article-title":"Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study","volume":"145","author":"Badros","year":"2025","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 t","volume":"25","author":"Moreau","year":"2024"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s2152-2650(25)03957-6","article-title":"Outcomes in second-line lenalidomide-refractory patients in the phase 3 DREAMM-7 study of belantamab mafodotin, bortezomib (V), and dexamethasone (d) vs daratumumab-Vd in RRMM DREAMM-7 study design","volume":"25","author":"Mateos","year":""},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281772","article-title":"Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020\u201304 study","volume":"108","author":"Talbot","year":"2023","journal-title":"Haematologica"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-025-01226-8","article-title":"A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma","volume":"15","author":"Dileo","year":"2025","journal-title":"Blood Cancer J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/bjh.18479","article-title":"Real-world experience with belantamab mafodotin therapy for relapsed \/ refractory multiple myeloma: a multicentre retrospective study","volume":"200","author":"Shragai","year":"2023"},{"key":"B29","doi-asserted-by":"publisher","first-page":"19507","DOI":"10.1200\/JCO.2024.42.16suppl.e19507","article-title":"Real-world analysis of belantamab mafodotin (belamaf): care patterns in relapsed \/ refractory multiple myeloma","volume":"3","author":"Patel","year":"2023"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2025.1008","article-title":"Characterization of belantamab mafodotin\u2013induced corneal changes in patients with multiple myeloma","volume":"19104","author":"Lee","year":"2025"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025018309","article-title":"Belamaf: is renal toxicity an overlooked side effect? Belamaf: is renal toxicity an overlooked side effect? Running title: Belantamab mafodotin associated proteinuria nephrology, dialysis and renal transplant unit, IRCCS \u2013 Azienda Ospedaliero-Universitaria IRCCS \u2013 Azienda Ospedaliero- Universitaria di Bologna, Istituto di Ematologia \u201c Ser\u00e0gnoli \u201d, Department of Medical and Surgical Science (DIMEC), Alma Mater Studiorum - University of Hematology Unit, Department of Translational and Precision Medicine Azienda Ospedaliera Policlinico Umberto I Sapienza University of Rome, Rome, Italy. Corresponding author: Gisella Vischini Ethical approval","volume":"10","author":"Vischini","year":"2026","journal-title":"Blood Adv"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12659\/AJCR.944681","article-title":"Focal and segmental glomerulosclerosis in a multiple myeloma patient after belantamab mafodotin therapy and severe COVID-19 infection: a case report","author":"Buob","year":"2024"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/nejmoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/ceor.s310619","article-title":"Budget impact of belantamab mafodotin (belamaf) adoption in the treatment of patients with relapsed or refractory multiple myeloma in the United States","volume":"10","author":"Shah","year":"2021"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43856-022-00097-5","article-title":"Global disparities in access to cancer care","volume":"2","author":"Dos-Santos-Silva","year":"2022"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967700.16100.68","article-title":"Oral abstract session LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed \/ refractory multiple myeloma","volume":"7","author":"Lee","year":"2023"},{"key":"B40","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000050","article-title":"g-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"6694","DOI":"10.2217\/fon-2020-1269","article-title":"Belantamab mafodotin in combination with novel agents in relapsed \/ refractory multiple myeloma: DREAMM-5 study design belantamab mafodotin in combination with novel agents in relapsed \/ refractory multiple myeloma: DREAMM-5 study design","volume":"17","author":"Nooka","year":"2021"},{"key":"B44","doi-asserted-by":"publisher","first-page":"8019","DOI":"10.1200\/JCO.2022.40.16suppl.8019","article-title":"Poster discussion session synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed \/ refractory multiple myeloma (RRMM): DREAMM-5 study","volume":"6","author":"Lonial","year":"2022"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients correspondence","volume":"102","author":"Ghermezi","year":"2017"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02766-5","article-title":"The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma","volume":"39","author":"Frede","year":"2025","journal-title":"Leukemia"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01114-7","article-title":"Sustained remission following finite duration bispecific antibody therapy in patients with relapsed \/ refractory myeloma","volume":"14","year":"2024"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023557","article-title":"Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma","volume":"144","author":"Firestone","year":"2024","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood.V130.Suppl_1.1840.1840","article-title":"Relapsed or refractory multiple myeloma patients treated with second-line carfilzomib and categorized by prior exposure to bortezomib: a subgroup analysis of the randomized phase 3 Aspire and Endeavor trials","volume":"130","author":"Mateos","year":"2017","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2030477","article-title":"Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide- based treatment in patients with multiple myeloma: updated efficacy, safety, and health- related quality of life results from the phase 2","volume":"63","author":"Bahlis","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70042","article-title":"Multicenter real \u2010 World study","volume":"18","author":"Furlan","year":"2025"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70260","article-title":"Sequencing BCMA \u2010 and GPRC5D \u2010 targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network","volume":"9","author":"van de Donk","year":"2025","journal-title":"Hemasphere."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01081-z","article-title":"Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma","volume":"14","author":"Rees","year":"2024","journal-title":"Blood Cancer J"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023616","article-title":"Efficacy and safety of teclistamab in patients with relapsed \/ refractory multiple myeloma after BCMA-targeting therapies","volume":"144","author":"Touzeau","year":"2024","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.06.015","article-title":"Real-world outcomes of sequential BCMA-directed therapies in relapsed refractory multiple myeloma after belantamab exposure","volume":"25","author":"Mewawalla","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026229","article-title":"Reengaging life post-BCMA for myeloma","volume":"144","author":"Quach","year":"2024","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3333","article-title":"T-cell characteristics impact response and resistance to T-cell-redirecting bispecific antibodies in multiple myeloma","volume":"30","author":"Verkleij","year":"2024","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0035","article-title":"Belantamab Mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses In Vivo","volume":"20","author":"Montes de Oca","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2025.100103","article-title":"Belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: a real-world experience","volume":"2","author":"Hultcrantz","year":"2025","journal-title":"Blood Neoplasia"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-025-01259-z","article-title":"Real-world evaluation of teclistamab for the treatment of relapsed \/ refractory multiple myeloma (RRMM): an International Myeloma Working Group Study","volume":"15","author":"Tan","year":"2025","journal-title":"Blood Cancer J"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMoa2514663","article-title":"Teclistamab plus daratumumab in relapsed or refractory multiple myeloma","volume":"324","author":"Costa","year":""},{"key":"B63","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11899-024-00748-5","article-title":"Navigating the economic burden of multiple myeloma: Insights into cost-effectiveness of CAR-T and bispecific antibody therapies","volume":"20","author":"Keesari","year":"2025","journal-title":"Curr Hematol Malig Rep"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016490","article-title":"Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels","volume":"9","author":"Banerjee","year":"2025","journal-title":"Blood Adv"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284694","article-title":"Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and\/or refractory multiple myeloma","volume":"109","author":"Mateos","year":"2024"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.04.002","article-title":"Feasibility and safety of outpatient model for administration of bispecific antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract","volume":"25","author":"Scott","year":"2025"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2373331","article-title":"Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma","volume":"65","author":"Dimopoulos","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21203\/rs.3.rs-3843028\/v1","article-title":"Novel anti-B-cell maturation antigen alpha-amanitin antibody-drug conjugate HDP-101 shows superior activity to belantamab mafodotin and enhanced efficacy in deletion 17p myeloma models","author":"Singh","year":""},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00208-8","article-title":"Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1 \/ 2a study","volume":"8","author":"Kelly","year":"2021","journal-title":"Lancet Haematol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00940","article-title":"Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"Trial. J Clin Oncol"},{"key":"B74","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2018.08.018","article-title":"A phase I study to assess the safety and pharmacokinetics of single-agent lorvotuzumab mertansine (IMGN901) in patients with relapsed and\/or refractory CD\u201356-positive multiple myeloma","volume-title":"Myeloma clin lymphoma myeloma leuk","author":"Ailawadhi","year":"2019"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70296","article-title":"Population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling of serum M-protein response for Modakafusp Alfa in a phase 1 \/ 2 study of patients with relapsed or refractory multiple myeloma","volume":"7","author":"Li","year":"2025","journal-title":"Clin Transl Sci"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.37349\/etat.2022.00067","article-title":"Exploration of targeted anti-tumor therapy antibody-drug conjugate therapies in multiple myeloma \u2014 what\u2019s next on the horizon","author":"Hartley-brown","year":"2022"},{"key":"B77","article-title":"Belantamab for the treatment of multiple myeloma: results from part1 of the first human phase 1\/2 DREAMM-20 trial","volume-title":"Oral ASCO annual meeting, June 1th 2025. J Clin Oncol","author":"Quach","year":""},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000445","article-title":"Options at the time of relapse after anti-BCMA therapy","volume":"2023","author":"Razzo","year":"2023","journal-title":"Hematol (United States)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1822419\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:31:31Z","timestamp":1781065891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1822419\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":78,"alternative-id":["10.3389\/fonc.2026.1822419"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1822419","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"article-number":"1822419"}}